A Prospective Randomized Controlled Trial to Study the Role of Sulfasalazine in the Prevention of Acute Gastrointestinal Toxicities in Patients of Carcinoma of the Cervix Receiving Concurrent Chemoradiation

Abstract

The present study aimed to evaluate the effectiveness of sulfasalazine in preventing acute gastrointestinal (GI) toxicities in patients with cervical carcinoma receiving concurrent chemoradiation. This prospective randomized controlled study was conducted at the Department of Radiotherapy from November 2016 to April 2018. A total of 60 eligible patients (30 in arm A and 30 in arm B) were enrolled in the study. Patients in arm A received 5,000 cGy of external beam radiotherapy (EBRT) in 25 fractions concurrently with chemotherapy using cisplatin (40 mg/m2 weekly) and tablet sulfasalazine (1 g twice a day). Patients in arm B received 5,000 cGy of EBRT in 25 fractions concurrently with chemotherapy using cisplatin (40 mg/m2 weekly) without any prophylactic medication. The acute GI toxicities assessed in this study included diarrhea, abdominal pain, tenesmus, and rectal bleeding. The chi-squared test was employed to compare the toxicity grades in the two arms. The collected data were analyzed using Statistical Package for Social Sciences (SPSS) version 21, with statistical significance considered at p < 0.05. The results showed a significant decrease in the incidence of grade 2 or higher diarrhea in the study arm compared to the control arm. Additionally, there was a decrease in the incidence of grade 1 or higher abdominal pain in the study arm. A decrease in the incidence of grade 1 or higher tenesmus was also observed, although the difference was not statistically significant. Rectal bleeding decreased significantly. Sulfasalazine was found to be a cost-effective and safe method for reducing the incidence of radiation-induced acute GI toxicities in cervical carcinoma patients undergoing radiotherapy.

Keywords

cervical carcinoma - chemoradiation - diarrhea - sulfasalazine - acute gastrointestinal toxicities

Publikationsverlauf

Artikel online veröffentlicht:
16. Oktober 2023

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Nandakumar A, Kishor Rath G, Chandra Kataki A. et al. Concurrent chemoradiation for cancer of the cervix: results of a multi-institutional study from the setting of a developing country (India). J Glob Oncol 2015; 1 (01) 11-22
• 3 Muls AC. Acta Oncologica Lecture. Gastrointestinal consequences of cancer treatment and the wider context: a bad gut feeling. Acta Oncol 2014; 53 (03) 297-306
• 4 Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. World J Gastrointest Surg 2015; 7 (11) 279-288
• 5 Rauch K, Weiland H. Therapy of radiogenic colitis with salicylazosulfapyridine (azulfidine)]. Strahlentherapie 1972; 143 (06) 660-663
• 6 Mennie AT, Dalley VM, Dinneen LC, Collier HO. Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet 1975; 2 (7942) 942-943
• 7 Khalid U, McGough C, Hackett C. et al. A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys 2006; 64 (05) 1432-1441
• 8 Loge L, Florescu C, Alves A, Menahem B. Radiation enteritis: diagnostic and therapeutic issues. J Visc Surg 2020; 157 (06) 475-485
• 9 Hamstra DA, Mariados N, Sylvester J. et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys 2017; 97 (05) 976-985
• 10 Both S, Deville C, Bui V, Wang KK, Vapiwala N. Emerging evidence for the role of an endorectal balloon in prostate radiation therapy. Transl Cancer Res 2012; 1 (03) 227-235
• 11 Lawrie TA, Green JT, Beresford M. et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev 2018; 1 (01) CD012529
• 12 Adli M, Mayr NA, Kaiser HS. et al. Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer?. Int J Radiat Oncol Biol Phys 2003; 57 (01) 230-238
• 13 Wiesendanger-Wittmer EM, Sijtsema NM, Muijs CT, Beukema JC. Systematic review of the role of a belly board device in radiotherapy delivery in patients with pelvic malignancies. Radiother Oncol 2012; 102 (03) 325-334
• 14 Resbeut M, Marteau P, Cowen D. et al. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 1997; 44 (01) 59-63
• 15 Baughan CA, Canney PA, Buchanan RB, Pickering RM. A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol) 1993; 5 (01) 19-24
• 16 Martenson Jr JA, Hyland G, Moertel CG. et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 1996; 35 (02) 299-303
• 17 Pal S, Adhikary S, Bhattacharya B, Basu J, Ghosh T, Patra N. A prospective randomized controlled trial to study the role of sulfasalazine in prevention of acute gastrointestinal toxicity associated with concurrent chemoradiation in carcinoma cervix. Clin Cancer Investig J 2013; 2 (02) 118-121
• 18 Miller RC, Petereit DG, Sloan JA. et al; Alliance for Clinical Trials in Oncology. N08C9 (Alliance): a phase 3 randomized study of sulfasalazine versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2016; 95 (04) 1168-1174
• 19 Kiliç D, Egehan I, Ozenirler S, Dursun A. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol 2000; 57 (02) 125-129